Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17066300 | 0.96 | CYP3A4 (0.45) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL17066336 | 0.95 | CYP3A4 (0.44) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL17066342 | 0.93 | CYP3A4 (0.42) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL17066339 | 0.91 | CYP3A4 (0.43) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL15992705 | 0.89 | CYP3A4 (0.55) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL17066337 | 0.88 | CYP3A4 (0.39) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL16062558 | 0.87 | CYP3A4 (0.43) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL12436388 | 0.87 | CYP3A4 (0.37) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL17066319 | 0.87 | CYP3A4 (0.55) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 | |
| SCHEMBL17066327 | 0.87 | CYP3A4 (0.42) | CYP3A4CYP2C9NR1I2KCNH2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | CYP3A4 241/4885CYP2C9 394/4885NR1I2 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.